| The rise of deep learning in drug discovery |
151 |
| Machine learning in chemoinformatics and drug discovery |
111 |
| The roles of ions on bone regeneration |
42 |
| Pharmaceutical nanocrystals: production by wet milling and applications |
41 |
| Pharmaceutical cocrystals: from serendipity to design to application |
37 |
| Artificial intelligence in drug development: present status and future prospects |
33 |
| NTM drug discovery: status, gaps and the way forward |
29 |
| Protein-peptide docking: opportunities and challenges |
29 |
| Luxturna: FDA documents reveal the value of a costly gene therapy |
29 |
| A bibliometric review of drug repurposing |
28 |
| Progress with covalent small-molecule kinase inhibitors |
28 |
| Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors |
28 |
| Role of IncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes |
26 |
| The next level in chemical space navigation: going far beyond enumerable compound libraries |
25 |
| ADMET modeling approaches in drug discovery |
25 |
| Neural network and deep-learning algorithms used in QSAR studies: merits and drawbacks |
25 |
| Cell membrane-coated nanocarriers: the emerging targeted delivery system for cancer theranostics |
25 |
| Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts |
24 |
| Repurposing host-based therapeutics to control coronavirus and influenza virus |
24 |
| Reshaping drug development using 3D printing |
23 |
| Carbon dots: emerging theranostic nanoarchitectures |
23 |
| Recent advances in siRNA delivery for cancer therapy using smart nanocarriers |
22 |
| Locked nucleic acid: modality, diversity, and drug discovery |
22 |
| Solid nanoparticles for oral antimicrobial drug delivery |
22 |
| Discovery of hidden allosteric sites as novel targets for allosteric drug design |
21 |
| Recent advances in pharmaceutical dosage forms and devices using additive manufacturing technologies |
21 |
| Applications of stimuli-responsive nanoscale drug delivery systems in translational research |
21 |
| Computational prediction of chemical reactions: current status and outlook |
21 |
| Recent advances in intra-articular drug delivery systems for osteoarthritis therapy |
20 |
| A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems |
20 |
| Recent advances in bacteriophage-based methods for bacteria detection |
19 |
| Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities |
19 |
| The use of nanoparticles as biomaterials in dentistry |
19 |
| Targeting intrinsically disordered proteins at the edge of chaos |
19 |
| Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys |
19 |
| Bioactive glasses entering the mainstream |
19 |
| Cyclodextrins as excipients in tablet formulations |
19 |
| Current potential and challenges in the advances of liquid crystalline nanoparticles as drug delivery systems |
18 |
| Therapeutic implications of nanomedicine for ocular drug delivery |
17 |
| Recent advances in near-infrared light-responsive nanocarriers for cancer therapy |
17 |
| Updates on the pathogenicity status of Pseudomonas aeruginosa |
17 |
| Therapy for glioblastoma: is it working? |
17 |
| The emerging role of copper-64 radiopharmaceuticals as cancer theranostics |
17 |
| Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties |
17 |
| Anticancer activity of palladium-based complexes against triple-negative breast cancer |
17 |
| PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges |
17 |
| Exosomal miRNA in chemoresistance, immune evasion, metastasis and progression of cancer |
16 |
| Mitochondrial permeability transition pore: a potential drug target for neurodegeneration |
16 |
| Present drug-likeness filters in medicinal chemistry during the hit and lead optimization process: how far can they be simplified? |
16 |
| Poloxamer-based in situ gelling thermoresponsive systems for ocular drug delivery applications |
16 |
